Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Phykion Inc. is currently addressing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner, ORDAZ, CHRISTIAN JOSE, within 1 distinct art unit. ORDAZ, CHRISTIAN JOSE is the busiest examiner for the portfolio, overseeing 1 pending office action.
The prosecution for this company is currently concentrated in a single application. The presence of only 1 distinct art unit indicates a specific technical focus within the biotechnology sector. With only 1 pending office action to manage, the applicant can dedicate significant resources to addressing the specific concerns of the assigned examiner.
The alignment of the technology area with the specific art unit suggests that the application is being reviewed by a specialist in biological systems. This allows for a concentrated effort to resolve the pending matter. The limited number of pending actions suggests a highly manageable prosecution pipeline at this stage. This focus ensures that the applicant can provide a comprehensive and detailed response to the examiner's findings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORDAZ, CHRISTIAN JOSE | 1 | 61.1% | +91.7% |
| JONES-FOSTER, ERICA NICOLE | 1 | 48.1% | +44.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18793396 | METHOD FOR NUCLEAR GENOME EDITING USING PLASTID SELECTABLE MARKERS | ORDAZ, CHRISTIAN JOSE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18386502 | RECOMBINANT ALGAE HAVING HIGH BIOMASS AND LIPID PRODUCTIVITY | JONES-FOSTER, ERICA NICOLE | 53d |
| 18793396 | METHOD FOR NUCLEAR GENOME EDITING USING PLASTID SELECTABLE MARKERS | ORDAZ, CHRISTIAN JOSE | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793396 | METHOD FOR NUCLEAR GENOME EDITING USING PLASTID SELECTABLE MARKERS | ORDAZ, CHRISTIAN JOSE | 1663 | §103§112 | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18386502 | RECOMBINANT ALGAE HAVING HIGH BIOMASS AND LIPID PRODUCTIVITY | JONES-FOSTER, ERICA NICOLE | 1656 | §112 | Final Rejection | 53d | Pending | Nov 02, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial